Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ADMENYSEAMERICAN:ASTCVE:STA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMEAptus Drawdown Managed Equity ETF$47.97+3.5%$45.86$39.85▼$48.57$236.38M0.7925,116 shs3,726 shsASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsSTASanatana ResourcesC$0.74+7.2%C$0.50C$0.08▼C$0.94C$75.36M1.32106,945 shs121,935 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMEAptus Drawdown Managed Equity ETF+0.41%+2.04%+3.55%+7.35%+9.72%ASTAsterias Biotherapeutics0.00%0.00%0.00%0.00%0.00%STASanatana Resources+7.25%+1.37%+1.37%+722.22%+770.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMEAptus Drawdown Managed Equity ETFN/AN/AN/AN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMEAptus Drawdown Managed Equity ETF 2.72Moderate Buy$48.040.15% UpsideASTAsterias Biotherapeutics 0.00N/AN/AN/ASTASanatana Resources 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMEAptus Drawdown Managed Equity ETFN/AN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AC$0.16 per share4.71C$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMEAptus Drawdown Managed Equity ETFN/AN/A25.80∞N/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ASTASanatana Resources-C$2.27M-C$0.01N/A∞N/AN/A-58.40%-54.68%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMEAptus Drawdown Managed Equity ETF$0.210.44%N/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMEAptus Drawdown Managed Equity ETFN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/ASTASanatana Resources3.475.532.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMEAptus Drawdown Managed Equity ETFN/AASTAsterias BiotherapeuticsN/ASTASanatana ResourcesN/AInsider OwnershipCompanyInsider OwnershipADMEAptus Drawdown Managed Equity ETFN/AASTAsterias BiotherapeuticsN/ASTASanatana Resources10.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMEAptus Drawdown Managed Equity ETFN/A4.59 millionN/ANot OptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableSTASanatana Resources3101.84 millionN/ANot OptionableADME, AST, STA, and UOG HeadlinesRecent News About These CompaniesSanatana Resources Inc. (STA.V) - Yahoo FinanceJune 28 at 10:31 AM | ca.finance.yahoo.comSanatana Resources (CVE:STA) Stock Price Down 1.4% - Time to Sell?June 24, 2025 | marketbeat.comOff-market insider buying at Sanatana Resources (STA)June 14, 2025 | theglobeandmail.comSanatana Resources (CVE:STA) Trading Up 16.9% - Still a Buy?June 11, 2025 | marketbeat.comSanatana Resources (CVE:STA) Shares Up 16.9% - Time to Buy?June 11, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading 17.9% Higher - Time to Buy?June 6, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading Up 16.4% - Time to Buy?June 6, 2025 | marketbeat.comSanatana Resources (CVE:STA) Trading Up 19.4% - Time to Buy?June 6, 2025 | marketbeat.comSanatana Resources (CVE:STA) Reaches New 1-Year High - Should You Buy?June 5, 2025 | marketbeat.comSanatana Announces Closing of the Acquisition of the Gold Strike Two Project and the Concurrent Oversubscribed Private PlacementJune 4, 2025 | finance.yahoo.comSanatana Resources Completes Acquisition and Raises $1.38M in Private PlacementJune 4, 2025 | tipranks.comStockTalk | Gold Report: Opportunities across the mining lifecycleMay 7, 2025 | msn.comSanatana adds Yukon gold project, stock jumps 150 per centMay 6, 2025 | msn.comSanatana Resources Enters into Definitive Agreement to Acquire 5,900 Hectare Gold Strike...May 5, 2025 | juniorminingnetwork.comSanatana Resources Announces Share Consolidation PlansDecember 16, 2024 | markets.businessinsider.comSanatana Resources Inc. (SADMF)November 23, 2024 | uk.finance.yahoo.comSanatana Drill Program Extends Known Mineralization at Oweegee Dome Porphyry Copper-Gold Project in BC's Golden TriangleNovember 12, 2024 | finance.yahoo.comSanatana Resources Drill Program Extends Known Mineralization at Oweegee Dome Porphyry Copper-Gold Project in BC's Golden TriangleNovember 12, 2024 | juniorminingnetwork.comSanatana Announces Resignation of DirectorNovember 4, 2024 | finance.yahoo.comSADMF Sanatana Resources Inc.October 14, 2024 | seekingalpha.comSanatana Resources (TSXV:STA) Completes 2024 Drill Program at Oweegee Dome Project, with Some Results PendingSeptember 17, 2024 | miningfeeds.comMMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI Spending3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not Hype3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong Recoveries3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryDon’t Miss These 2 Small Quantum Stocks Poised to PopBy Gabriel Osorio-Mazilli | June 24, 2025View Don’t Miss These 2 Small Quantum Stocks Poised to PopADME, AST, STA, and UOG Company DescriptionsAptus Drawdown Managed Equity ETF BATS:ADME$47.97 +1.64 (+3.54%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Aptus Drawdown Managed Equity ETF (ADME) is an exchange-traded fund that mostly invests in large cap equity. The fund is actively managed to select large-cap US stocks that exhibit positive fundamental and momentum characteristics combined with a downside hedge. ADME was launched on Jun 8, 2016 and is managed by Aptus.Asterias Biotherapeutics NYSEAMERICAN:AST$0.0020 0.00 (0.00%) As of 07/10/2019Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.Sanatana Resources CVE:STAC$0.74 +0.05 (+7.25%) As of 06/30/2025 03:59 PM EasternSanatana Resources Inc., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties. It explores for copper and gold. The company entered in an option agreement to acquire 80% interest in the Oweegee Dome project covering an area of approximately 31,077 hectares located in in Golden Triangle in British Columbia; and 100% interest in the Empress Property, as well as asset purchase agreement to acquire the Santoy Property comprising 32 cell mining claims covering an area of approximately 551 hectares located in in Ontario. It also holds interests in the Fortune Project consisting of 100% interest in the Enid property, which comprises 41 mineral claims in the Timmins, Ontario region. The company was formerly known as Sanatana Diamonds Inc. and changed its name to Sanatana Resources Inc. in April 2011. Sanatana Resources Inc. was incorporated in 2004 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
